RecruitingEarly Phase 1NCT04390009

Entire-body PET Scans for Multiple Sclerosis

Exploratory Study of Entire-body PET Scans for Multiple Sclerosis


Sponsor

Brain Health Alliance

Enrollment

20 participants

Start Date

Sep 30, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

To evaluate whether an entire-body positron emission tomography (PET) scanner can be exploited to improve evaluation, monitoring and measurement of both peripheral and central demyelination in multiple sclerosis (MS) patients.


Eligibility

Min Age: 25 YearsMax Age: 55 Years

Inclusion Criteria3

  • Multiple sclerosis (MS) patients diagnosed by a credentialed neurologist experienced with care of multiple sclerosis patients.
  • Normal healthy subjects.
  • Willing and able to lie motionless on the PET-CT scanner bed for at least 10 minutes and up to 20 minutes for the duration of the PET-CT medical imaging scan.

Exclusion Criteria6

  • Any additional complicating medical illness other than MS including any other neuropsychiatric illness unrelated to MS diagnosed prior to the onset of initial symptoms of MS.
  • Pregnancy or breast feeding.
  • Diabetes or other metabolic-endocrine disorders.
  • Any known concomitant acute infection.
  • History of metastatic or locally invasive cancer.
  • Recent surgery, chemotherapy or radiation therapy.

Interventions

DIAGNOSTIC_TESTEntire-body PET-CT scans

Entire-body PET-CT scans will be performed with state-of-the-art scanners with different manufacturers' models including Siemens Biograph Vision, United Imaging uEXPLORER and possibly other recently FDA-approved PET-CT scanners.

DRUGAmyvid radiopharmaceutical

Amyvid (F18-florbetapir) will be evaluated for binding to white matter of the peripheral and central nervous system of participants


Locations(1)

Brain Health Alliance

Ladera Ranch, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04390009


Related Trials